Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Amortization of Deferred Charges (2018 - 2025)

Historic Amortization of Deferred Charges for Tg Therapeutics (TGTX) over the last 8 years, with Q3 2025 value amounting to $304000.0.

  • Tg Therapeutics' Amortization of Deferred Charges fell 2657.0% to $304000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 4787.64%. This contributed to the annual value of $2.0 million for FY2024, which is 1610.6% down from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Amortization of Deferred Charges is $304000.0, which was down 2657.0% from $304000.0 recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Amortization of Deferred Charges ranged from a high of $639000.0 in Q2 2023 and a low of $231000.0 during Q1 2021
  • In the last 5 years, Tg Therapeutics' Amortization of Deferred Charges had a median value of $461000.0 in 2022 and averaged $435684.2.
  • In the last 5 years, Tg Therapeutics' Amortization of Deferred Charges surged by 9956.71% in 2022 and then tumbled by 5258.22% in 2024.
  • Quarter analysis of 5 years shows Tg Therapeutics' Amortization of Deferred Charges stood at $386000.0 in 2021, then increased by 19.43% to $461000.0 in 2022, then skyrocketed by 38.61% to $639000.0 in 2023, then crashed by 52.58% to $303000.0 in 2024, then grew by 0.33% to $304000.0 in 2025.
  • Its last three reported values are $304000.0 in Q3 2025, $304000.0 for Q2 2025, and $304000.0 during Q1 2025.